Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Teduglutide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,798,327Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Combo drugs: latest trend in local pharmaceuticals
    Combo drugs: latest trend in local pharmaceuticals

    19 Aug 2019

    // Lee Hye-seon KOREAMED

    http://www.koreabiomed.com/news/articleView.html?idxno=6300

    Lee Hye-seon KOREAMED
    19 Aug 2019
    Share Share
    U.S. FDA Approves GATTEX® for Children 1Y Age&Older With Short Bowel Syndrome
    U.S. FDA Approves GATTEX® for Children 1Y Age&Older With Short Bowel Syndrome

    17 May 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-approves-gattex-teduglutide-for-children-1-year-of-age-and-older-with-short-bowel-syndrome-sbs-300852294.html

    PR NEWSWIRE
    17 May 2019
    Share Share
    Shire Moves to Protect Gattex From Par Generic Challenge
    Shire Moves to Protect Gattex From Par Generic Challenge

    31 Jul 2018

    // BLOOMBERG

    https://news.bloomberglaw.com/pharma-and-life-sciences/shire-moves-to-protect-gattex-from-par-generic-challenge?context=landing-heroes

    BLOOMBERG
    31 Jul 2018
    Share Share
    Gattex (teduglutide), Amlodipine and Valsartan Tabs : Shire-NPS Pharm v. Par Pharma et al.
    Gattex (teduglutide), Amlodipine and Valsartan Tabs : Shire-NPS Pharm v. Par Pharma et al.

    30 Jul 2018

    // PATENT LITIGATION

    https://www.pharmacompass.com/pdf/news/gattex-teduglutide-amlodipine-and-valsartan-tabs-shire-nps-pharm-v-par-pharma-et-al-1533038693.pdf

    PATENT LITIGATION
    30 Jul 2018
    Share Share
    SMC endorses five new therapies for NHS Scotland
    SMC endorses five new therapies for NHS Scotland

    10 Apr 2018

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/smc_endorses_five_new_therapies_for_nhs_scotland_1231056

    Selina McKee PHARMA TIMES
    10 Apr 2018
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Gattex (Teduglutide) Injection
    FDA Confirms Paragraph IV Patent Challenge of Gattex (Teduglutide) Injection

    03 Mar 2018

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-gattex-teduglutide-injection-1520057039.pdf

    FDA
    03 Mar 2018
    Share Share